PADI4 and psoriasis: In line with this, PAD4 (peptidyl arginine deaminase 4) may serve as a biomarker for the quantification of treatment response in psoriasis patients undergoing anti-TNF-α biological therapy (with Adalimumab or Infliximab), as significant decrease in PAD4 serum levels along with improvements in clinical severity scores was observed.